Majbritt Busk Madsen

Majbritt Busk Madsen

Auto-generated profile, based on publicly available information

Majbritt Busk Madsen

Department of Veterinary and Animal Sciences University of Copenhagen Frederiksberg C Denmark

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Journal of Heredity
Verified
Journal Article
Open access
PDF file
MMMajbritt Busk Madsen
Majbritt Busk Madsen
LOLisbeth Høier Olsen
Lisbeth Høier Olsen
JHJens Häggström
Jens Häggström
KHKatja Höglund
Katja Höglund
ILIngrid Ljungvall
Ingrid Ljungvall
MFMerete Fredholm
Merete Fredholm
Myxomatous mitral valve disease (MMVD) is the most common heart disease in dogs. It is characterized by chronic progressive degenerative lesions of the mitral valve. The valve leaflets become thickened and prolapse into the left atrium resulting in mitral regurgitation (MR). MMVD is most prevalent in small to medium sized dog breeds, Cavalier King Charles Spaniels (CKCS) in particular. The onset of MMVD is highly age dependent, and at the age of 10 years, nearly all CKCS are affected. The incidence of a similar disease in humans—mitral valve prolapse—is 1–5%. By defining CKCSs with an early onset of MMVD as cases and old dogs with no or mild signs of MMVD as controls, we conducted a genome-wide association study (GWAS) to identify loci associated with development of MMVD. We have identified a 1.58 Mb region on CFA13 ( Pgenome = 4.0× 10 −5 ) and a 1.68 Mb region on CFA14 ( Pgenome = 7.9× 10 −4 ) associated with development of MMVD. This confirms the power of using the dog as a model to uncover potential candidate regions involved in the molecular mechanisms behind complex traits.

17 December 2009 in Animal Biotechnology
Verified
Journal Article
Closed access
MMMajbritt Busk Madsen
Majbritt Busk Madsen
MBMalene M. Birck
Malene M. Birck
MFMerete Fredholm
Merete Fredholm
SCSusanna Cirera
Susanna Cirera
Obesity is an increasing problem worldwide and research on candidate genes in good animal models is highly needed. The pig is an excellent model as its metabolism, organ size, and eating habits resemble that of humans. The present study is focused on the characterization of the fat mass and obesity associated gene (FTO) in pig. This gene has recently been associated with increased body mass index in several human populations. To establish information on the expression profile of FTO in the pig we performed quantitative PCR in a panel of adult pig tissues and in tissues sampled at different developmental stages. Expression of the FTO transcript was detected in all tissues tested with significantly higher levels in brain tissues (cortex, cerebellum, and hippocampus; P < 0.001). These levels varied through the development and between the specific parts of the brain studied (i.e., frontal cortex and cerebellum). Additionally, in order to see the involvement of the FTO gene in obesity, the changes in expression level were investigated in a nutritional study in brain of Göttingen minipigs under a high cholesterol diet. Significantly higher (P < 0.01) levels of FTO transcript were found in cortex when compared with cerebellum of the high-cholesterol fed pigs. Furthermore, SNPs were investigated in the coding sequence of the FTO in the Göttingen minipig and in the Danish commercial pig. Eleven synonymous SNPs and a two bp insertion were found between the two pig lines.

3 December 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KNKarl Emil Nelveg-Kristensen
Karl Emil Nelveg-Kristensen
MMMajbritt Busk Madsen
Majbritt Busk Madsen
CTChristian Torp-Pedersen
Christian Torp-Pedersen
LKLars Køber
Lars Køber
MEMartin Egfjord
Martin Egfjord
PHPeter Riis Hansen
Peter Riis Hansen
Evidence for pharmacogenetic risk stratification of angiotensin-converting enzyme inhibitor (ACEI) treatment is limited. Therefore, in a cohort of ACEI-treated patients with congestive heart failure (CHF), we investigated the predictive value of two pharmacogenetic scores that previously were found to predict ACEI efficacy in patients with ischemic heart disease and hypertension, respectively. Score A combined single nucleotide polymorphisms (SNPs) of the angiotensin II receptor type 1 gene (rs275651 and rs5182) and the bradykinin receptor B1 gene (rs12050217). Score B combined SNPs of the angiotensin-converting enzyme gene (rs4343) and ABO blood group genes (rs495828 and rs8176746). Danish patients with CHF enrolled in the previously reported Echocardiography and Heart Outcome Study were included. Subjects were genotyped and categorized according to pharmacogenetic scores A and B of ≤1, 2 and ≥3 each, and followed for up to 10 years. Difference in cumulative incidences of cardiovascular death and all-cause death were assessed by the cumulative incidence estimator. Survival was modeled by Cox proportional hazard analyses. We included 667 patients, of whom 80% were treated with ACEIs. Differences in cumulative incidences of cardiovascular death (P = 0.346 and P = 0.486) and all-cause death (P = 0.515 and P = 0.486) were not significant for score A and B, respectively. There was no difference in risk of cardiovascular death or all-cause death between subjects with score A ≤1 vs. 2 (HR 1.03 [95% CI 0.79–1.34] and HR 1.11 [95% CI 0.88–1.42]), score A ≤1 vs. ≥3 (HR 0.80 [95% CI 0.59–1.08] and HR 0.91 [95% CI 0.70–1.20]), score B ≤1 vs. 2 (HR 1.02 [95% CI 0.78–1.32] and HR 0.98 [95% CI 0.77–1.24]), and score B ≤1 vs. ≥3 (HR 1.03 [95% CI 0.75–1.41] and HR 1.05 [95% CI 0.79–1.40]), respectively. We found no association between either of the analyzed pharmacogenetic scores and fatal outcomes in ACEI-treated patients with CHF.

1 November 2021 in The Application of Clinical Genetics
Verified
Journal Article
Open access
PDF file
AJAnne Marie Jelsig
Anne Marie Jelsig
ABAnna Byrjalsen
Anna Byrjalsen
MMMajbritt Busk Madsen
Majbritt Busk Madsen
TKTine Plato Kuhlmann
Tine Plato Kuhlmann
THThomas van Overeem Hansen
Thomas van Overeem Hansen
JKJohn Gásdal Karstensen
John Gásdal Karstensen
Hereditary polyposis syndromes are characterized by a large number and/or histopathologically specific polyps in the gastrointestinal tract and a high risk of both colorectal cancer and extracolonic cancer at an early age. While the genes responsible for some of the syndromes, eg, APC in familial adenomatous polyposis and STK11 in Peutz-Jeghers syndrome, have been known for decades, novel genetic causes have recently been detected that have shed light on the broader clinical spectrum of syndromes. Genetic diagnoses are important because they can facilitate a personalized surveillance program. Furthermore, at-risk members of the patient’s family can be tested and enrolled in surveillance as needed. In some cases, prenatal diagnostics should be offered. In this paper, we describe the development in germline genetics of the hereditary polyposis syndromes over the last 10– 12 years, their clinical characteristics, as well as how to implement genetic analyses in the diagnostic pipeline.

1 April 2016 in Pharmacogenetics and Genomics
Verified
Journal Article
Closed access
KNKarl Emil Nelveg-Kristensen
Karl Emil Nelveg-Kristensen
MMMajbritt B. Madsen
Majbritt B. Madsen
CTChristian Torp-Pedersen
Christian Torp-Pedersen
LKLars Køber
Lars Køber
MEMartin Egfjord
Martin Egfjord
PHPeter Riis Hansen
Peter Riis Hansen
Objective Most angiotensin-converting enzyme inhibitors (ACEIs) are prodrugs activated by carboxylesterase 1 (CES1). We investigated the prognostic importance of CES1 gene (CES1) copy number variation and the rs3815583 single-nucleotide polymorphism in CES1 among ACEI-treated patients with congestive heart failure (CHF). Methods Danish patients with chronic CHF enrolled in the previously reported Echocardiography and Heart Outcome Study were categorized according to their CES1 variants and followed up for up to 10 years. Risk for cardiovascular death and all-cause death was modeled by Cox proportional hazard analyses. Results A total of 491 ACEI-treated patients were included in the analyses. After a mean follow-up of 5.5 years, we found no difference in the risk for cardiovascular death and all-cause death between patients having three [hazard ratios (HRs) 1.06 (95% confidence interval (CI) 0.77–1.45) and 1.16 (95% CI 0.88–1.52)] or four [HRs 0.88 (95% CI 0.39–2.01) and 1.37 (95% CI 0.74–2.54)] CES1 copies and those with two copies, respectively. Similarly, no difference in the risk for cardiovascular and all-cause death was found for patients heterozygous [HRs 0.91 (95% CI 0.70–1.19) and 0.88 (95% CI 0.69–1.12)] or homozygous [HRs 0.58 (95% CI 0.30–1.15) and 0.82 (95% CI 0.48–1.39)] for the rs3815583 minor allele versus patients homozygous for the major allele. The active promoter of CES1A2 and the rs71647871 single-nucleotide polymorphism minor allele were detected at very low frequencies. Conclusion This study did not support the use of CES1 copy number variation or rs3815583 as a predictor of fatal outcomes in ACEI-treated patients with CHF.

1 March 2015 in Pharmacogenetics and Genomics
Verified
Journal Article
Closed access
DBDitte Bjerre
Ditte Bjerre
LFLaura Ferrero
Laura Ferrero
MMMajbritt Madsen
Majbritt Madsen
PHPeter Riis Hansen
Peter Riis Hansen
HRHenrik B. Rasmussen
Henrik B. Rasmussen